As Partner and Head of Life Sciences at The Marbury Law Group, Michelle E. O’Brien brings scientific depth and legal precision to matters where the stakes are measured in clinical timelines and years of exclusivity. She knows that a robust patent portfolio is key to protecting innovations that are critical to the value of her clients no matter their size—whether for strengthening negotiating leverage for partnerships and financing for start-ups, or preserving long-term competitive advantage and market exclusivity for large corporations.
About Michelle E. O'Brien
What sets Ms. O’Brien apart is her strategic, 360-degree approach, shaped by more than 25 years on both sides of patent disputes. Michelle has built and fortified patent portfolios from the ground up, challenged competitor patents through USPTO proceedings, and has acted as litigation counsel for both patentees and accused infringers in court. Having spent her career pressure-testing patents the way challengers do, she spots vulnerabilities early and delivers the kind of durable patent position that can withstand scrutiny and help secure long-term market exclusivity. To ensure her counsel is both technically and legally sound, Ms. O’Brien immerses herself in the underlying chemistry and biology involved in each matter so that she understands it the way the inventors—and a potential challenger—would.
That depth of understanding allows her to capture and leverage every meaningful nuance, whether in drafting and prosecuting a patent or advising on broader IP strategy. For companies in the chemical, pharmaceutical, and life sciences industries with IP needs ranging from patent application drafting and prosecution to portfolio strategy and counseling to high-stakes litigation, Ms. O’Brien offers the scientific credibility, strategic perspective, and litigation experience to protect what they have built and position them for what comes next.
Technical Expertise
Ms. O’Brien’s technical practice is concentrated in the areas where science and commercial value intersect most directly. Her work spans areas of chemical and pharmaceutical innovation and life sciences, including new chemical entities, novel formulations, and life-cycle management strategies, as well as solid-state sciences, advanced materials (polymer chemistry, ceramics, glass technology, adhesives, and paper science), and consumer goods, including specialty chemicals, food science, personal care products, and cosmetic chemistry. Clients across these sectors rely on her not only to secure rights, but to secure the right rights: patent portfolios built to withstand challenge and support long-term exclusivity.
Post-Grant Proceedings & PTAB
As patent disputes have increasingly moved to the Patent Trial and Appeal Board (PTAB), Ms. O’Brien has built a practice at the center of that shift. She represents clients on both sides of inter partes review and post-grant review proceedings, whether challenging a competitor’s blocking patent or mounting a defense against a validity attack on a core commercial asset. Her work also includes complex reissue and reexamination proceedings as well as appellate advocacy before the Federal Circuit, where the outcome of a single proceeding can reshape a company’s competitive position for a generation.
Litigation & Pre-Litigation Expertise
Ms. O’Brien has experience litigating patent infringement cases, including Hatch-Waxman (ANDA) and consumer product patent cases. From pre-suit investigation and Paragraph IV certifications through discovery and trial, she has provided the kind of integrated strategic counsel that clients need when the stakes are high. Even when not directly involved, Michelle often provides litigation support as other lawyers regularly call on her to help their clients win due to her depth of knowledge and understanding of patent law and practice.
Patent Portfolio Strategy & Counseling
Much of Ms. O’Brien’s most consequential work happens before litigation becomes necessary—often positioning clients to avoid the courtroom altogether. Her counseling practice encompasses rigorous gap analyses to remediate potential weaknesses in a patent portfolio, freedom-to-operate clearances that provide the certainty required for successful product launches, and competitive landscape assessments that identify white space available for innovation. Michelle also serves as a long-term strategic advisor to many of her clients by helping align their patent portfolios with their commercial roadmaps, for example by optimizing patent life through strategies including Patent Term Extension, Patent Term Adjustment, and obtaining patent protection on clinical trial results.
Thought Leadership
Ms. O’Brien is a recognized voice and leader in the international IP community. She has taught at AIPLA’s Patent Prosecution Bootcamp and AIPLA’s Advanced Chemical/Pharma Patent Practice Institute. Michelle routinely lectures on various topics such as inventorship, inequitable conduct, infringement, and written description, keeping her clients informed of how emerging legal developments translate into practical risk and opportunity. Some of her recent presentations include Written Description: Lessons From Duke v. Sandoz and Seagen v. Daiichi Sankyo (Feb. 2026), Examining Pharmaceutical Patent Term Extensions: Patent Term Adjustment and Patent Term Restoration (Oct. 2025), Obviousness-Type Double Patenting, PTA, and PTEs: Defeating ODP Rejections, Avoiding Terminal Disclaimers (April 2025), Drafting and Prosecuting Patent Applications to Survive a Markman Hearing (May 2024), and In-Licensing and Out-Licensing in the Pharmaceutical Industry (Feb. 2024). Ms. O’Brien’s recent publications include J. Brougher, T. Irving & M. O’Brien, Orange Book Listings Under Scrutiny: What’s In, What’s Out, and Why It Matters, 18 Int’l In-House Couns. J. No. 70, 1 (Winter 2025), and A. Lacy & M. O’Brien, Crystal Clear? Patentability of Polymorphs in Europe and the U.S., AIPLA Chem. Prac. Chronicles, Spring 2025, 13:1.
Ms. O’Brien earned her J.D. from Georgetown University Law Center and her undergraduate degree in chemistry from the University of Toledo. She is admitted to practice in Maryland, the District of Columbia, the U.S. Patent and Trademark Office, and the Court of Appeals for the Federal Circuit. She is also an active member of AIPLA’s Chemical Practice Committee.
Work & Education History
Education
- Georgetown University Law Center (J.D.)
- University of Toledo (B.A. Chemistry, cum laude)
Admissions
- Maryland
- District of Columbia
- Registered Patent Attorney (USPTO)
- U.S. Court of Appeals for the Federal Circuit
Memberships
- American Intellectual Property Law Association (AIPLA)
- American Bar Association
- Maryland Bar Association
- Bar Association of the District of Columbia
- American Chemical Society



